Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire) - Oct 19, 2026 - "Additional posters will highlight emerging translational and real-world evidence, including an indirect comparison suggesting that lifileucel may approximately double four-year overall survival rates compared with standard-of-care therapies in anti-PD-1-resistant advanced melanoma...Poster (Abstract #2117P): Indirect Comparison of Overall Survival (OS) between Lifileucel versus Standard-of-Care (SoC) in US Real-World Settings in Anti-PD-1 Resistant Advanced Melanoma; Poster (Abstract #2125P): Lifileucel versus Nivolumab plus Relatlimab (NIVO+RELA) in Anti-PD-(L)1-Resistant Advanced Melanoma: A Match-Adjusted Indirect Comparison (MAIC) of Efficacy Outcomes"
P2 data • Real-world evidence • Melanoma
|